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Computer-aided design of human sialyltransferase inhibitors of hST8Sia III
Abstract
Sialyltransferase (ST) upregulation and the resultant hypersialylation of tumour cell surfaces is an
established hallmark of many cancers including lung, breast, ovarian, pancreatic and prostate cancer. The
role of ST enzymes in tumour cell growth and metastasis, as well as links to multi-drug resistance, has
seen ST inhibition emerge as a target for potential antimetastatic cancer treatments. The most potent of
these reported inhibitors are transition-state analogues. Although there are several examples of these in
the literature, many have suspected poor pharmacokinetic properties and are not readily synthetically
accessible. A proposed solution to these problems is the use of a neutral carbamate or 1,2,3-triazole
linker instead of the more commonly used phosphodiester linker, and replacing the traditionally utilised
cytidine nucleotide with uridine. Another issue in this area is the paucity of structural information of
human ST enzymes. However, in late 2015 the structure of human ST8Sia III was reported (only the
second human ST described so far), creating the opportunity for structure-based design of selective ST8
inhibitors for the first time. Herein, molecular docking and molecular dynamics simulations with the newly
published crystal structure of hST8Sia III were performed for the first time with selected ST transition
state analogues. Simulations showed that these compounds could participate in many of the key
interactions common with the natural donor and acceptor substrates, and reveals some key insights into
the synthesis of potentially selective ST inhibitors.
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Abstract: Sialyltransferase (ST) upregulation and the resultant hypersialylation of tumour cell
surfaces is an established hallmark of many cancers including lung, breast, ovarian, pancreatic
and prostate cancer. The role of ST enzymes in tumour cell growth and metastasis, as well as
links to multi-drug resistance, has seen ST inhibition emerge as a target for potential
antimetastatic cancer treatments. The most potent of these reported inhibitors are transitionstate analogues. Although there are several examples of these in the literature, many have
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suspected poor pharmacokinetic properties and are not readily synthetically accessible. A
proposed solution to these problems is the use of a neutral carbamate or 1,2,3-triazole linker
instead of the more commonly used phosphodiester linker, and replacing the traditionally
utilised cytidine nucleotide with uridine. Another issue in this area is the paucity of structural
information of human ST enzymes. However, in late 2015 the structure of human ST8Sia III
was reported (only the second human ST described so far), creating the opportunity for
structure-based design of selective ST8 inhibitors for the first time. Herein, molecular docking
and molecular dynamics simulations with the newly published crystal structure of hST8Sia III
were performed for the first time with selected ST transition state analogues. Simulations
showed that these compounds could participate in many of the key interactions common with
the natural donor and acceptor substrates, and reveals some key insights into the synthesis of
potentially selective ST inhibitors.
Keywords: sialyltransferase; inhibitors; molecular docking; molecular dynamics simulations;
ST8Sia; transition-state analogues; metastasis
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INTRODUCTION
Hyperglycosylation of tumour cells, in particular hypersialylation due to overexpression of
sialyltransferases (STs) is a well-established hallmark of cancer, which makes the development
of selective inhibitors a vital area of inquiry in cancer treatment.[1-3] STs are enzymes of the
glycosyltransferase family that catalyse the formation of an α-glycosidic bond between the C2
atom of a sialic acid (N-acetylneuraminic acid, or Neu5Ac) and a hydroxyl group of a glycan
acceptor.[4-5] In humans all, STs utilise the common donor cytidine monophosphate Neu5Ac
(CMP-Neu5Ac). There are 20 different human sialyltransferase enzymes which catalyse the
biosynthesis of cell surface glycoconjugates.[6-8] These subtypes are each expressed in different
cell types, potentially allowing for specific targeting of the enzymes, which are overexpressed
in many forms of cancer such as colorectal,[9-10] breast,[11] and pancreatic cancer.[12] Selective
targeting of specific ST subtypes has been shown to be crucial in order to avoid off-target
effects such as liver and kidney dysfunction (in mice), which has been observed for global
inhibitors.[13]
STs are named according to the position of the glycosidic bond that they catalyse, and the
glycan acceptor to which the sialic acid is bound. In humans four families of STs exist, which
catalyse the formation of an α-glycosidic linkage between the 2′ position of the sialic acid donor
and the 3′, 6′, and 8′ hydroxyl group of the glycan acceptor.[5] These are classified as ST3, ST6,
and ST8 respectively, followed by the sugar molecule to which they form the linkage (e.g. Gal,
GalNAc, Sia). The ST8Sia subfamily (of which there are six members) catalyse an α-2,8
linkage between two sialic acids, while having different specificities for the length of the sialic
acid acceptor. Within this subfamily, ST8Sia III is the only member which shows a specificity
for oligosialic acids.[14]
ST8Sia III is a membrane-bound enzyme fixed to the Golgi apparatus, with the catalytic
domain located in the lumen (Figure 1).[4] In the literature, ST structures have been resolved
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for nine species of bacteria[4,15-22] and only four different mammalian structures.[7,14,23-24] The
porcine ST3Gal I (pST3Gal I)[23] was resolved in 2009, both rat[24] and human[7] ST6Gal I
(rST6Gal I and hST6Gal I respectively) in 2013, and most recently in 2015, the structure of
human ST8Sia III (hST8Sia III)[14] has been determined, co-crystallised with various
substrates, such as 5'-O-[(R)-[(S)-[3-(acetylamino)phenyl](phosphono)methoxy](hydroxy)
phosphoryl] cytidine (55T).[25] These new structures allow for comparisons to be made between
binding sites, to investigate potential avenues for selective inhibitor design.
Previous studies into ST inhibitors have identified transition-state analogues as the most potent
reported to date.[2,26-28] These compounds mimic the planar oxocarbenium-like transition-state
of the ST mechanism, using the sialic acid donor CMP-Neu5Ac (1) as a starting point (Figure
2). Some of the earliest compounds (such as 2, Ki = 350 nM; α-2,6-ST) added a planar bond to
the sialic acid mimic, and replaced the carboxylate group with a phosphonate, giving markedly
improved activity.[29] Replacing the sialic acid mimic with a simpler meta-phenoxy aromatic
system, resulted in a further increase in potency giving one of the most potent human ST
inhibitors to date, compound 3 (Ki = 19 nM; hST6Gal I ).[30-31] However, there are perceived
pharmacokinetic issues with this compound, as it is believed that the phosphodiester linkage
may be susceptible to cleavage by phosphatases in vivo (and potentially cleavage by the STs
themselves, as the CMP leaving group is still present), rendering the compound inactive.[32] To
address this issue, it has been proposed that replacing the charged phosphodiester linkage with
a neutral carbamate (4), or 1,2,3-triazole (6), group could improve drug-likeness of the
inhibitors.[33-34] Another potential alteration to the lead compound 3 is the exchange of the
cytidine moiety with a uridine (5 and 7), in order to aid synthetic accessibility and to probe
potential selectivity between ST subtypes.
The aim of this study is to develop an understanding of the specificities of ST8Sia III by
computational analysis of ligand-protein interactions, using compounds 4-7 as a starting point.
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With comparison with previous work on ST6Gal I,[33,35] this will inform the rational design of
potent and selective ST inhibitors with favourable pharmacokinetic properties.
METHODS
General Docking Procedure: Potential inhibitors (4-33) were docked into the binding site of
one monomer of the hST8Sia III crystal structure (PDB ID:5CXY)[25] with AutoDock Vina
(AD-Vina) version 1.1.2.[36] Receptor structures were prepared for docking using
AutoDockTools (ADT) version 4.2.6.[37] The three-dimensional structure of the inhibitors were
prepared utilising ChemDraw 15.0 and Avogadro v1.1.1.[38] ADT was used to assign both rigid
and rotatable bonds and to remove non-polar hydrogens. Docking was performed for a box of
30 Å × 30 Å × 30 Å centred at the active site. The dimension was chosen to ensure it was large
enough to cover all key active site residues identified in hST8Sia III by Volkers et al.[14] and
to accommodate the largest ligand investigated herein. The docking procedure was validated
by re-docking to replicate the crystallographically determined hST8Sia III-55T complex
(Figure 1). The receptor is treated as rigid and no explicit waters have been included. The top
ranked models for each compound tested based on the binding affinities calculated by ADVina were evaluated based upon comparison to the position of 55T in the crystal structure of
hST8Sia III (Figure 1)[25] with VMD v1.9.2.[39] Ranking of inhibitors according to docking
results was further validated by docking compounds with known inhibition values from
biological testing (unpublished data – personal communication, Gerardy-Schahn, R). Statistical
analysis was undertaken on the calculated binding affinities for each compound to determine
if they were statistically different from one another, using a two-tailed students t-test. Results
were deemed significant for P < 0.05.
Molecular Dynamics Simulations: Molecular systems for MD simulations were prepared
using VMD v1.9.2.[39] For simulations involving a ligand, the ligand was docked into the
crystal structure using AD Vina according to the method above (See Table 1 for a description
5

of the simulations carried out). The simulated ligands varied in the linker used; carbamate
(CAR), 1,2,3-triazole (TRI), and phosphodiester (LEAD). The system was prepared by
solvating the protein crystal structure in a water box, with a space of at least 9.0 Å from each
side of the surface of the protein. The water box was also ionised with NaCl to a concentration
of 0.15 mol/L. MD simulation was carried out with NAMD 2.11,[40] and the force fields used
were the CHARMM PARAM36 force field for the protein,[41] and force field parameters
specific to the ligands which were generated by Montgomery et al.[33] using cGenFF[42] and
optimised using the GAAMP method.[43-44] The systems were simulated in periodic boundary
conditions using the Langevin algorithm for maintaining the temperature at 298.15 K, and the
Langevin Piston Nose-Hoover method to keep the pressure constant at 1.0 bar.[45-46] Van der
Waals forces were treated with a cut-off distance of 12.0 Å with a smoothening function
between 10.0 and 12.0 Å , while electrostatic interactions were calculated using the Particle
mesh Ewald method.[47] Covalent bonds involving hydrogen had their rigidity maintained by
the RATTLE algorithm.[48] The integration time step was set to 1.0, 2.0, and 4.0 fs for bonded,
non-bonded, and long range electrostatic interactions respectively. Triplicated equilibrium
simulations were undertaken for each system, for the first 10 ns with a harmonic restraint placed
upon the Cα atoms of the protein with a decreasing force constant over the 10 ns. The force
was halved every nanosecond of simulation, starting from 32.0 kcal/mol/Å2 until the force
constant reached 1.0 kcal/mol/Å2, which was applied for the remainder of the first 10 ns of
simulation. The simulations were then run for a further 90 ns without any restraints, with
snapshots saved every picosecond (1000 steps). In total, 1.9 microseconds of simulations were
carried out.
RMSD and RMSF Analysis: In order to analyse the structural changes in the protein over the
course of the simulations, root-mean-square deviation (RMSD) of protein Cα atoms and
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ligands, and root-mean-square fluctuation (RMSF) of Cα atoms with respect to the starting
structure were calculated for the course of each simulation, using VMD v1.9.2.[39]
ST8Sia III-ligand Interaction Analysis: For the MD simulations performed, key interactions
were analysed using CHARMM v.38a1,[49] according to specific criteria. Hydrogen bonds were
defined by a maximum donor-acceptor distance of 3.0 Å, and minimum donor-hydrogenacceptor angle of 120°, with minimum 10% occupancy. Water-bridged hydrogen bonds were
defined via the same variables, with a minimum of 30 % occupancy. Hydrophobic contacts
were defined by a maximum distance between hydrophobic atom pairs of 4.0 Å, with minimum
10% occupancy.
RESULTS AND DISCUSSION
Investigation of hST8Sia III crystal structure
The crystal structure of hST8Sia III was recently published by Volkers et al.[14] in 2015. In the
study, hST8Sia III was crystallised as an apo structure, and with three substrates; cytidine
diphosphate (CDP), cytidine triphosphate (CTP) and the natural donor mimic CMP-3FNeu5Ac
(along with the acceptor Sia-6S-LacNAc). It was also demonstrated that hST8Sia III adopts a
dimeric structure in solution, which is believed to contribute to stabilisation and membrane
tethering, rather than a change in activity.[14] This is contrary to the ST8Sia II and IV subtypes,
which appear to be monomeric.[14] There was a flexible loop observed in hST8Sia III over the
active site between residues Lys341-His354, which was not fully resolved in all but one crystal
structure (hST8Sia III co-crystallised with CDP). This indicates that the loop is highly
disordered, which is proposed to adopt a number of conformational states. There is also a
hydrophobic patch above the donor binding site (Lys349-Ser353), which is believed to play a
role in acceptor specificity within the ST8Sia enzyme family.[14] The His354 residue is believed
to be a catalytic residue for ST8Sia III, and is observed interacting with the O8′ of the acceptor
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sialic acid.[14] To date, there have been no computational studies performed on hST8Sia III for
the purposes of inhibitor design and so herein is described the first of this type performed on
this enzyme. A crystal structure was also released on the PDB by Volkers & coworkers in 2016
with ST8Sia III co-crystallised with 5'-O-[(R)-[(S)-[3-(acetylamino)phenyl](phosphono)
methoxy](hydroxy)phosphoryl]cytidine (55T), which has a comparable structure to the lead
ST inhibitor (3, Figure 2).[25] These recent developments indicate the potential for development
of selective inhibitors, with the availability of multiple crystal structures of these human ST
enzymes giving the opportunity for structure-based drug design for the first time.
Comparison between binding sites of pST3Gal I, hST6Gal I, and hST8Sia III
To gain an insight into the potential structural features of selective hST8Sia III inhibitors,
structural alignment of three mammalian STs (pST3Gal I, hST6Gal I, and hST8Sia III) was
performed using BIOVIA Discovery Studio Visualizer,[50] centred around the donor molecule
binding pocket (Figure 3). It was observed that for both pST3Gal I (85 % homology to hST3Gal
I) and hST8Sia III, there was a hydrophobic sub-pocket adjacent to the 2′ position on the ribose
ring of the co-crystallised ligands (shown by the colour gradient in Figure 3). Hydrophobicity
was calculated using the method of Kyte and Doolittle, which assigns a value to each amino
acid based on its hydrophobicity.[51] These values then contribute to the averaged surface
hydrophobicity. There is also a sub-pocket present in the hST6Gal I structure, although it was
smaller than in the other two subtypes, and offset from the 2′ position. This indicates that
pST3Gal I and hST8Sia III may tolerate inhibitors with substitutions on the 2′ position, while
hST6Gal I will not, as has been shown experimentally.[2] It appears that the sub-pocket
mentioned is also larger for pST3Gal I than for hST8Sia III, which could lead to further
selectivity between the two (if hST3Gal I adopts the same binding pocket structure).
Stability and flexibility of the hST8Sia III-ligand complexes
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The effects of ligand binding on the structural stability and flexibility of hST8Sia III over the
course of the MD simulations were assessed. The RMSD of protein carbon alphas (Cα) for all
simulations converged between 1.5 and 2.5 Å (Figure S1-S7), indicating that there was no
significant change in the overall structure of the protein. The heavy atom positional RMSD of
the ligand in the carbamate (CAR) simulations converged between 1.5 and 2.5 Å (Figures S8
and S9), the phosphodiester (LEAD) simulations converged between 2.0 and 2.5 Å (Figures
S10 and S11), triazole (TRI) simulations converged between 2.0 and 3.5 Å (Figures S12 and
S13), except for one of the (S)-triazole (TRI_S) simulations, which stabilised at 1.5 Å. This
indicates that the more flexible carbamate and phosphodiester linked compounds were better
able to fit in the binding site of ST8Sia III and adopt a more stable conformation, as opposed
to the more rigid triazole compound. In terms of the RMSF of the protein Cα atoms, all ligandprotein complex simulations exhibited lower RMSF values for the flexible loop from Lys341
to His354 than those observed for the apo simulation, which peaked at 3.5 Å (Figure 4). This
effect is due to favourable ligand-protein interactions that serve to stabilise the loop. Of these
simulations, the triazole complexes exhibited the smallest change in RMSF for the loop, which
was between 1.5 and 3.5 Å (Figure S16). This may be due to the rigidity of the triazole linker,
which necessitates additional movement by the protein to accommodate it.
Comparison of the binding modes of carbamate- and 1,2,3-triazole-linked inhibitors with
hST8Sia III
Docking of potential inhibitors (4-27) of ST8Sia III and their phosphodiester equivalents (3,
28-38) into snapshots (20 ns intervals from 0-100 ns) from the carbamate simulation (CAR_R1)
was undertaken (results from statistical analysis in Tables S1-S17). The compounds were
chosen based on a previous study by Montgomery et al,[33] to assess their difference in binding
against hST6Gal I. Statistical analysis was performed to determine if the differences between
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the calculated binding affinities were significant. The analysis gave a wide range of p-values,
ranging from 7.16 ×10-6 to 1 across different comparison pairs.
Across all compounds analysed, there was no significant difference between the binding
affinities of the R and S stereoisomers of the same compounds. Although this is
counterintuitive, this result correlates with previously observed experimental and
computational results for other STs.[30,33] This appears to be due to the relatively larger space
available in the binding site, while still allowing for the ligand to interact with residues that are
key for binding.
There was also no significant difference in the binding affinities of cytidine (3, 4, 6, 8-12, 1822, 28-32) and uridine (5, 7, 13-17, 23-27, 33-38) derivatives of the same compounds (Table
2, 3 and 4). This suggests that there may be no specificity observed in hST8Sia III for cytidinebased compounds over uridine based. This could open a door to selective inhibitor design, as
the cytidine moiety is believed to be crucial to the activity of hST6Gal I inhibitors (although
there is experimental evidence that hST3Gal I could also accept uridine derivatives).[2,7] The
two derivatives also exhibited near-identical predicted binding modes (Figure 5A). This result
suggests that uridine derivatives of ST inhibitors may be selective against ST6Gal I, and that
they may be a viable (and more synthetically accessible) alternative than their cytidine
equivalents.
The phosphodiester-linked compounds tested did not show any significant differences in
binding affinity compared to their carbamate- and 1,2,3-triazole-linked equivalents, suggesting
that the use of carbamate and 1,2,3-triazole linkers do not have any major effect on the binding
mode of these potential ST inhibitors.
While not statistically significant in the majority of cases, it was noted that each 1,2,3-triazolelinked derivative produced a greater binding affinity than its carbamate-linked equivalent (with
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the single exception of (R)-11 exhibiting a higher average binding affinity than (R)-21, which
was greater by 0.1 kcal/mol, a difference which was not statistically significant). This result
indicates that the differences in binding affinities of compounds with 1,2,3-triazole- and
carbamate-linkers are not significant and in fact comparable to one another.
In terms of the binding modes of the potential inhibitors, it was noted that there were two main
binding pockets towards which the sialyl mimic segment of the inhibitor was directed, with a
third conformation being less frequent (demonstrated in Figure 5B). This indicates that there
is a reasonable degree of flexibility in the structure of potential inhibitors in the region
traditionally occupied by the sialyl mimic.
Effect of 2′ substitution on inhibitor binding
To probe the effect on binding of substitutions at the 2′ position of ST inhibitors and to what
degree they may be accommodated by the binding pocket of hST8Sia III, docking was
performed with uridine-based carbamate derivatives (5, 39-44, Table 5). It was found that there
was no significant difference between the calculated binding affinities of the compounds with
substitutions up to the size of a propoxy group and the non-substituted compound (R)-5
(Table 5). Inhibitors with substitutions larger than this (such as a benzyl group) were not able
to adopt a suitable binding conformation, indicating a limit to the size tolerance of the subpocket.
Analysis of binding interactions between hST8Sia III and potential inhibitors
Analyses were performed on the protein-ligand complex MD simulations as part of this work
to determine the consistent hydrogen bonds and hydrophobic contacts between the ligands and
protein. These interactions were then compared to the non-bonded interactions described by
Volkers et al.,[14] identified in the X-ray crystal structures of hST8Sia III with donor and
acceptor analogues (Figure 6). When comparing the protein-ligand interactions observed in the

11

MD simulations, there was a greater similarity between the carbamate (CAR) and
phosphodiester (LEAD) simulations than with the triazole (TRI) simulations.
The carbamate (CAR) and phosphodiester (LEAD) simulations were found to more closely
mimic the interactions observed in the hST8Sia III crystal structure complex, compared to the
TRI simulations. This may be due to the increased rigidity of the triazole linker, meaning that
the ligand was less able to adopt a conformation which matched the donor and acceptor
analogues. Key similarities between the carbamate (CAR) and phosphodiester (LEAD)
simulations are shown in Figure 7. Two residues that had consistent interactions in both the
simulations and the crystal structure include Asn167 and Thr301. The residue Asn167 was
observed interacting with the phosphate group of the donor analogue, while in the carbamate
(CAR) and phosphodiester (LEAD) simulations it was involved in hydrogen bonding with the
cytidine N6 and ribose oxygen. In the case of the R stereoisomers, Asn167 also participated in
hydrogen bonding with the carbamate and phosphodiester linkers, which indicate that they are
effectively mimicking the phosphate of the donor analogue. In the crystal structure, Thr301
was observed interacting with the carboxylate group of CMP-3FNeu5Ac, where as in the MD
simulations it was interacting with the linker (in the case of the carbamate compounds), the
3′-hydroxyl, and in the phosphodiester (LEAD) simulations, the phosphonate group, which is
intended to be an analogue of the carboxylate. One key difference that was observed across the
stereoisomers of the carbamate (CAR) and phosphodiester (LEAD) simulations were that the
linker at the R stereoisomers was interacting with the Asn190 residue, while the linker of the S
stereoisomers was interacting with His337 via a water-bridged hydrogen bond. Both residues
are noted to interact with the phosphonate group of CMP-3FNeu5Ac in the crystal structure.
This expands upon previous work by Montgomery et al.[33] on hST6Gal I, and indicates that
the carbamate linker is effective at mimicking the phosphodiester linker of the earlier ST
inhibitors.
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Other hydrogen bonding interactions which were consistent between both the R and S
stereoisomers which were not explicitly noted by Volkers et al.[14] These include the residues
Tyr336, Trp322, and Ser168, which all had hydrogen-bonding interactions with the cytidine
moiety, while Gly302 had interactions with both 2′ and 3′ hydroxyl groups. These residues
appear to be important in helping to orient the nucleotide fragment of the inhibitors in the active
site, while also allowing the sialyl mimic of the inhibitor to adopt a more favourable
conformation in the hydrophobic pocket of the active site.
In terms of hydrophobic contacts observed over the course of the MD simulations for the
carbamate (CAR) and phosphodiester (LEAD) ligands, there were five residues which had
conserved interactions across R and S stereoisomers of both ligands (Figure 8). These residues
include Phe321, Tyr336, His337, His354, and Leu356. It was interesting that there was only
one conserved interaction with the aromatic region of the ligands, that being between the
catalytic residue His354 and the aromatic sialyl mimic, when it occupies a large hydrophobic
pocket, as observed by Volkers et al.[14] A potential explanation for this observation is that
while occupancies for specific interactions were lower than 10 %, there is a large number of
hydrophobic residues in that region, resulting in a wide variety of hydrophobic contacts being
made throughout the simulations. Since His354 was observed in the crystal structure to interact
(albeit via hydrogen bonding) with the sialyl acceptor, these results indicate that these potential
inhibitors are effective at mimicking the planar transition-state of the ST mechanism.
While results from the triazole (TRI) simulations were less consistent with the crystal structure
than those for the carbamate (CAR) and phosphodiester (LEAD) simulations, the proteinligand interactions that were observed give an insight into inhibitor design for selective
ST8Sia III inhibitors. Two hydrogen bonding interactions that were consistent with the
hST8Sia III crystal structure were noted (Figure 9A), with Asn167 and Thr301 being the
residues involved in binding to the cytidine oxygen and triazole linker, respectively.
13

Hydrophobic contacts for the triazole (TRI) simulations were consistent with the carbamate
(CAR) and phosphodiester (LEAD) simulations for the cytidine moiety, with variations at the
sialyl mimic (Figure 9B). The triazole (TRI) simulations exhibited more consistent
hydrophobic interactions with the sialyl mimic, with the residues Pro246, Phe249, and Phe250
(which interacted with each of the aromatic rings in the separate R and S simulations). The
greater consistency in hydrophobic interactions with the sialyl mimic for the triazole (TRI)
simulations as opposed to the carbamate (CAR) and phosphodiester (LEAD) could be due to
the relative rigidity of the triazole linker. This would mean that the sialyl mimic is less mobile
in the binding pocket, and more consistent interactions are observed when compared to the
simulations with more flexible interactions.
Implications for the design of selective ST inhibitors
Previous work by our group has highlighted the suitability for carbamate and 1,2,3-triazole
linkers as isosteres of the charged phosphodiester group of classical ST inhibitors, particularly
for ST6Gal I.[33-34] The results found in this study show a similar observation for inhibitors of
ST8Sia III, with comparable binding patterns and interactions observed (particularly for the
carbamate-linked inhibitors). The results of this study showed no significant difference in the
calculated binding affinity of inhibitors bearing a uridine or cytidine moiety, which provides
support for the use of uridine as a nucleotide base for ST inhibitors, particularly for ST8Sia III.
This could be a route for the synthesis of selective inhibitors if it is found that uridine
derivatives have a lessened binding affinity for other ST subtypes such as ST6Gal I. Results
from both docking and MD also indicate that there is little difference in the binding modes and
interactions between R and S stereoisomers of the same inhibitor.
While there was little significant difference between the predicted binding affinities of the
triazole and carbamate derivatives of the inhibitors analysed here, there was a trend of triazole
compounds exhibiting a slightly higher binding affinity. Conclusive characterisation of such
14

effects will require rigorous binding free energy calculations. Additionally, and perhaps most
importantly for the development of selective inhibitors, is the observation that the binding
pocket of ST8Sia III can accommodate substitution at the 2′ position of ST inhibitors without
a detrimental effect to their binding affinity. This is in contrast to ST6Gal I, which does not
accommodate such substitutions.[2] These observations should be probed further and may yield
promising results in the realm of selectivity, at the very least against ST6Gal I.
CONCLUSIONS:
Computational analysis of potential inhibitor binding was performed using the crystal structure
of hST8SiaIII for the first time. A validated docking procedure was used to assess 42 distinct
compounds and their stereoisomers. The results suggested that there was no significant
difference in the predicted binding affinity of inhibitors bearing either a uridine or cytidine
nucleotide moiety. Docking results also showed that there was no significant difference
between the binding affinity of the R and S diastereomers of the proposed inhibitors. MD
simulations determined that the proposed carbamate- and triazole-linked transition state
analogues bound to the hST8Sia III active site in a similar conformation to the co-crystallised
inhibitor analogue 55T, and the donor and acceptor analogues from the published crystal
structures, while retaining some key interactions with the protein. This work provides a
foundation for more rigorous characterisation of binding affinities and selectivities based on
free energy calculations, which is currently underway. Furthermore, current studies also
provide important insights for the synthetic and biological exploration of 2′-substituted
carbamate and 1,2,3-triazole-linked ST inhibitors, which display a potential for selectivity.
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Table 1: Summary of MD simulations performed
Ligand
None
(R)-4
(S)-4
(R)-3
(S)-3
(R)-6
(S)-6

Simulation Name
APO
CAR_R
CAR_S
LEAD_R
LEAD_S
TRI_R
TRI_S

Equilibrium steps (ns)
10
10
10
10
10
10
10

20

Free Simulation (ns)
90
90
90
90
90
90
90

Simulations Performed
1
3
3
3
3
3
3

Table 2. Mean binding affinities against hST8Sia III of carbamate-linked ST inhibitors based on multiple docking calculations.

R

Cpd

Mean Binding
Affinity
(kcal/mol)a

Cpd

Mean Binding
Affinity
(kcal/mol)a

(R)-8
(S)-8

-9.5 ± 0.2
-9.3 ± 0.1

(R)-13
(S)-13

-9.5 ± 0.2
-9.5 ± 0.1

(R)-4
(S)-4

-10.5 ± 0.2
-10.4 ± 0.3

(R)-5
(S)-5

-10.7 ± 0.2
-10.3 ± 0.2

(R)-9
(R)-9

-10.0 ± 0.2
-10.0 ± 0.2

(R)-14
(R)-14

-10.1 ± 0.1
-10.1 ± 0.3

(R)-10
(S)-10

-9.9 ± 0.3
-9.7 ± 0.1

(R)-15
(S)-15

-10.0 ± 0.3
-9.9 ± 0.1

(R)-11
(S)-11

-9.5 ± 0.1
-9.3 ± 0.1

(R)-16
(S)-16

-9.5 ± 0.1
-9.5 ± 0.2

(R)-12
(S)-12

-9.4 ± 0.1
-9.3 ± 0.2

(R)-17
(S)-17

-9.4 ± 0.2
-9.4 ± 0.2

a

Arithmetic mean of binding affinity ± SEM obtained from docking into six snapshots of
the CAR_R1 simulation.
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Table 3. Mean binding affinities against hST8Sia III of 1,2,3-triazole-linked ST inhibitors, based on multiple docking
calculations.

R

Cpd

Mean Binding Affinity
(kcal/mol)a

Cpd

Mean Binding Affinity
(kcal/mol)a

(R)-18
(S)-18

-9.8 ± 0.1
-10.1 ± 0.2

(R)-23
(S)-23

-10.0 ± 0.1
-9.7 ± 0.3

(R)-6
(S)-6

-10.9 ± 0.3
-11.0 ± 0.3

(R)-7
(S)-7

-10.8 ± 0.2
-11.0 ± 0.3

(R)-19
(S)-19

-10.1 ± 0.2
-10.5 ± 0.2

(R)-24
(S)-24

-10.3 ± 0.2
-10.6 ± 0.2

(R)-20
(S)-20

-10.2 ± 0.2
-10.6 ± 0.3

(R)-25
(S)-25

-10.1 ± 0.2
-10.5 ± 0.2

(R)-21
(S)-21

-9.4 ± 0.1
-9.9 ± 0.2

(R)-26
(S)-26

-9.7 ± 0.1
-10.2 ± 0.2

(R)-22
(S)-22

-9.8 ± 0.1
-10.0 ± 0.2

(R)-27
(S)-27

-9.7 ± 0.1
-10.1 ± 0.2

a

Arithmetic mean of binding affinity ± SEM obtained from docking into six snapshots of the
CAR_R1 simulation.
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Table 4. Mean binding affinities against hST8Sia III of phosphodiester-linked ST inhibitors, based on multiple docking
calculations.

R

Cpd

Mean Binding Affinity
(kcal/mol)a

Cpd

Mean Binding Affinity
(kcal/mol)a

(R)-28
(S)-28

-9.3 ± 0.1
-9.3 ± 0.2

(R)-33
(S)-33

-9.3 ± 0.2
-9.4 ± 0.1

(R)-3
(S)-3

-10.2 ± 0.3
-10.3 ± 0.2

(R)-34
(S)-34

-10.3 ± 0.3
-10.3 ± 0.2

(R)-29
(S)-29

-9.7 ± 0.2
-9.8 ± 0.3

(R)-35
(S)-35

-10.0 ± 0.2
-10.1 ± 0.3

(R)-30
(S)-30

-9.8 ± 0.1
-9.9 ± 0.1

(R)-36
(S)-36

-9.8 ± 0.2
-9.8 ± 0.2

(R)-31
(S)-31

-9.2 ± 0.2
-9.4 ± 0.2

(R)-37
(S)-37

-9.3 ± 0.1
-9.5 ± 0.2

(R)-32
(S)-32

-9.2 ± 0.1
-9.3 ± 0.1

(R)-38
(S)-38

-9.3 ± 0.1
-9.4 ± 0.2

a

Arithmetic mean of binding affinity ± SEM obtained from docking into six snapshots of the
CAR_R1 simulation.
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Table 5: Mean binding affinities against hST8Sia III of potential ST inhibitors with 2′ substitutions

Mean Binding Affinity
(kcal/mol)a
H
(R)-5
-10.7 ± 0.2
(R)-39
Me
-10.9 ± 0.3
(R)-40
Et
-10.6 ± 0.2
(R)-41
Pr
-10.2 ± 0.2
(R)-42
CF3
-10.3 ± 0.2
(R)-43
CH2CF3
-10.8 ± 0.2
(R)-44
C 6H 5
Not accommodated
a
Arithmetic mean of binding affinity ± SEM obtained from docking into six snapshots of the CAR_R1
simulation.
R

Cpd
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Figure Legends
Figure 1: The structure of hST8Sia III (PDB id:5CXY)[25], which was crystallised with the
ligand 55T (blue). The soluble catalytic domain of hST8Sia III extends into the lumen of the
Golgi apparatus via a stem region from a transmembrane domain (TMD) and a short N-terminal
cytoplasmic domain. The flexible active-site loop (residues 341-354) is coloured in red.
Figure 2: Development of ST transition-state analogue inhibitors, from the one of the earliest
(2),[29] to the most potent inhibitor to date (3),[30-31] which serves as our lead. Comparisons of
carbamate (4 and 5), and 1,2,3-triazole (6 and 7) derivatives with the lead compound will be
the focus of this study.
Figure 3: Comparison between the donor binding sites of pST3Gal I (left - bound to CMP;
PDB id: 2WNB),[23] hST6Gal I (centre - bound to CMP; PDB id: 4JS2),[7] and hST8Sia III
(right - bound to 55T; PDB id: 5CXY),[25] with the surface showing the hydrophobicity of the
binding pocket, calculated according to the method of Kyte and Doolittle.[51]
Figure 4: Cα RMSFs of hST8Sia III, calculated for each MD simulation. Expanded figures are
in supplementary information (Figures S14-S16).
Figure 5: (A) Comparison between the predicted binding modes of the m-phenoxy cytidine
compound (R)-4 (green) and the analogous uridine compound (R)-5 (orange). (B); Comparison
of binding conformations of the sialyl mimic of inhibitor (R)-4, with the orange conformation
being the most common. The green binding mode gave generally higher binding affinity, with
lower frequency, while the pink mode was the least frequently suggested by the docking
procedure.
Figure 6: Significant non-bonded interactions described by Volkers et al.[14] of the donor and
acceptor analogues CMP-3FNeu5Ac and Sia-6S-LacNAc respectively, with hST8Sia III. Some
bonding interactions involving the protein backbone and the cytidine ring of CMP-3FNeu5Ac
are not displayed.
Figure 7: Significant hydrogen bonding interactions of the (A) R and (B) S stereoisomers of
the carbamate (CAR) and phosphodiester (LED) compounds with hST8Sia III across 90 ns of
simulation. Blue residues denote those interactions which were also observed in the crystal
structure. The red box represents the two linkers. Full interaction data shown in Tables S18,
S20, S22, and S24.
Figure 8: Significant hydrophobic interactions of the (A) R and (B) S stereoisomers of the
CAR and LED simulations with hST8Sia III across 90 ns of simulation. The red box represents
the two linkers. Full interaction data shown in Tables S19, S21, S23, and S25.
Figure 9: Significant non-bonded interactions of triazole (TRI) with hST8Sia III across 90ns
of free simulation in each of the six triazole (TRI) simulations. (A) Hydrogen bond analysis
(blue residues denote those interactions which were also observed in the crystal structure), (B)
hydrophobic contacts (grey residues denote interactions which were consistent in simulations
of one stereoisomer). Full interaction data is shown in Supplementary Tables S26-S29.
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